NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Valion Bio, Inc. (VBIO) Stock Analysis

Valion Bio, Inc. (VBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VBIO

$2.77

−$0.03 (−1.07%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VBIO with… →

VBIO Key Statistics

As of Sep 4, 2026
Trading
Open
$2.90
Previous Close
$2.80
Day's Range
2.72–2.99
52-Week Range
2.70–80.20
Volume
71.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.79
Valuation
Market Cap
$2.46M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−181.83
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$8.88M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
887.59K
1-Year Return
−4.81%
Dividend and dates
Avg Volume
386.08K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VBIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+91.03%
2025−75.35%
2024−80.78%
2023−97.19%
2022−83.51%
2021 (partial year)−25.24%

As of September 4, 2026.

VBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$8.88M—
2024$0.00−$5.66M—
2023$1.18M−$8.24M−701.0%
2022$1.84M−$10.10M−548.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$7.90M−$8.88M—
2024$0.00$2.00K−$4.48M−$5.66M—
2023$1.18M$287.00K−$8.25M−$8.24M−701.0%
2022$1.84M$299.00K−$10.10M−$10.10M−548.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VBIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricVBIOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Valion Bio, Inc. (VBIO) at $2.46M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 52 employees.

The most recent close on file for VBIO is $2.77, dated September 4, 2026. That is −$0.03 (−1.07%) against the previous close. The 52-week range on file runs from $2.70 to $80.20. The latest close sits 2.59% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $8.88M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −181.83.

Across the 4 fiscal years on file, revenue moves from $1.84M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.79. Annualized volatility over the trailing 4 years is 1,196.85%. Over the trailing twelve months the price has returned −4.81%. Measured over 3 years, that is −62.50% a year compounded.

Growth & Income

The record shows no dividend for VBIO.

The strongest complete calendar year on file is 2025 at −75.35%; the weakest is 2023 at −97.19%. Of the 4 complete calendar years on file, 0 finished higher. So far in 2026 the price is +91.03%.

Peer Comparison

Valion Bio, Inc. (VBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Valion Bio, Inc. VBIO $2.46M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Valion Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Valion Bio, Inc.

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Visit website →